Agios Pharmaceuticals (AGIO) Cash from Operations (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Cash from Operations data on file, last reported at 57312000.0 in Q2 2026.

• Quarterly Cash from Operations rose 25.69% year-over-year to 57312000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 360596000.0 (up 11.18% YoY) and the FY2025 annual result came in at 372977000.0, up 4.33% from the prior year.
• Cash from Operations rose to 57312000.0 in Q2 2026, from 118920000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 57312000.0 in Q2 2026 to a low of 133167000.0 in Q4 2024.
• A 5-year average of 85810555.56 and a median of 80671000.0 in 2024 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations surged 36.72% — and 2024, when it sank 83.71%.
• Tracing AGIO's Cash from Operations over 5 years: stood at 66163000.0 in 2022, then decreased by 9.56% to 72488000.0 in 2023, then slumped by 83.71% to 133167000.0 in 2024, then gained by 27.75% to 96213000.0 in 2025, then soared by 40.43% to 57312000.0 in 2026.
• The last three Cash from Operations figures came in at 57312000.0 (Q2 2026), 118920000.0 (Q1 2026), and 96213000.0 (Q4 2025), per Business Quant data.